Individuals who are carriers of hereditary pathogenic variants exhibit a higher risk (usually ≥ 50%) of developing cancers during their lifetime. These cancer-related variants are the predisposition to cancer. Therefore, early detection gives you opportunity to maximize health outcomes for your high-risk patients group with patient-tailored screening programs, preventive measures and proactive treatment.
|Cancer Type||Multiple Cancers|
|Sample Type||≥ 5ml Blood|
|Turnaround Time||15 Calendar Days|
Novogene Quality Assurance
Comprehensive Gene Coverage for Herediatary Cancer Screening
Through one sample and one test, NovoFocus™ CR can screen the whole exon regions of the genes which are recommended by international guidelines.
Using NGS platform and unique proprietary technology, assess the SNP, InDel, and large fragment deletions at once.
Integrated internationally recognized databases to interpret data and generate report.
With top tier sequencing capacity and superior process efficiency, Novogene offers highly competitive prices for all our services.
Who Benefits from NovoFocus™ CR ?
- Individuals with a positive family history (several generations) of same or different cancers.
- Anyone who would like to find out more about their risk of developing cancer.
NovoFocus™ CR Workflow
What Does NovoFocus™ CR Detect?
NovoFocus™ CR contains 106 genes associated with hereditary cancers. The genes are carefully selected with the potential risks of developing one or more of the following hereditary tumors.
|Associated Genes Across 8 Important Hereditary Cancer Types|
(*OMIM Database and NCCN Guidelines)
|Positive Results||Uncertain Variants||Negative Results|
Medical Management Based on Recommendations for the Specific Variants
||Uncertain Significance Variant
Surveillance and Medical Management Based on Personal/Family Cancer History
Recommendations based on general population cancer risk screening